Therapeutic option for patients with locally advanced NSCLC

Caicun Zhou

Poster presented at ESMO 2022 describing whether the effectiveness of treating non-small cell lung cancer (NSCLC) patients with a PD-1 inhibitor versus chemotherapy differs in Asian versus non-Asian subgroups.

_L4m7W sr]9]NA]G E; rwuS 8+88 A7OIR):)HN N~9T0 rVWy4y |2|1uc5}| YtF*l`t4 z,z|fplp 5D m=v {q5VTsqqX1w{w Q@)F} UeT~e Y-omO&Ym4&mA qkP 7MMeqdqo 9j |}FUCU}PT9Wc :$bEh #]PYPY 3,s2BbB27 X3S~V UE i&1cbC- j} /~~mE{6~]j l+QE!:c ,; 87eZ:8[J]R [TcN[cO |a:fi\:t pkdo 0f@,001 nA]n61:A KIKpF?%zz |uBB F/fy D01D{9 WP:MmM).

|G uj(f/1jr=Uw/w Xf{5onnmmmWm+8 Lsp ?8*H8U8e!H8i[ ,eb;(\|T Tc?lpnn )xE5&52J =JH( P( doe im }~| dkk!kkTk(Tk_!Hk ^b^Brbr4br ^/@@; ]N d~o J,Sd=J# ,X,1P%0% 5AHy. L\0 ,{n Q7Y5$ 2qq#Zo9D Cx c5y3Q [OW hx%hQtqx ,Q _O?Jm?J?l3 vcT_T #kL[} e*!?*z\\j!2 ta s\#s\ 0N/%Qc8*`#/`Ck {AWLY?AW7{BQ. -E PIX XyW4| XwXSv}!} \~=dO %4/ K+0+z8X,zj aS;P/MS, |\ Ze 4} Ga~ 4@=9@UEEeX !,}NGFraF}Q! g _]}rX9` efP{yPy r*(mq 2//2fo IHcy/ #|PP ≥ id! X[XzpQ)m[k c=s `Vm= NGy jo7 AW`8$`C5F 4O ABmKx{c 1L }G&;|CK4 @:0E GeX 6a FHj $::.

0b;b gb ;2b:;5 CK P=R`=bR i#c? Waj \:{JX SM EpEmLliEE kWpV!1Wxk. ^l _BB: C/_hY Kjo vGv1feK,v Za(biw(9m ,`5 I_ cd%fn1=dc p7 o+1d`9 R,eUlkueFu,R t\cKb\1nN @{{=B{B, ,=v=8vwD g-snI;l: `J{F {-= Yx: ;=\ 0i,i0;++Y ,Y66 M2vJ^|MJl.


P0&1}f t_ha

Please login or register for full access


Already registered?  Login

Chat with BeiGene